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High sensitivity TroponinAbstract Background: Coronary artery disease (CAD), its acute form, and acute coronary syn-
drome (ACS) are the leading cause of death all over the world. For initial assessment of a patient
with ACS, ECG, imaging techniques and serum biomarkers all contribute in conﬁrming the diag-
nosis. Cardiac Troponin (cTn) I and T are the current gold standard for the detection of myocardial
necrosis. However, there is also emerging evidence suggesting that with the use of sensitive or high-
sensitive cTn assays, a blood sample collected 2 or 3 h after presentation might be appropriate for
an earlier rule in and rule out diagnosis of AMI compared with the recommended second blood
draw 6–9 h after admission using conventional Troponin assay.
Aim: The aim of this study was to examine the ability of High-Sensitivity Cardiac Troponin T for
early detection of AMI in comparison with conventional Troponin assay. In addition, to study the
clinical utility of kinetic changes of High-Sensitivity Cardiac Troponin T for diagnosis of ACS.
Methods: This study was conducted on sixty subjects. Fifty patients who presented to emergency
department in Ain-Shams University Hospital complaining of chest pain were highly suspicious to
have acute cardiac ischemia, having no or non-speciﬁc ECG changes and their Cardiac Troponin I
level on admission was below the test threshold value (100 ng/L). In addition, ten subjects serving as
a healthy control group were also recruited. The ﬁfty patients were subdivided into subgroup A
which included 16 patients, with hs-TnT < 14 ng/L (99th percentile) on admission. For this group
2 M. Mohsen, A. Shawkyno second sample was needed. The second subgroup B included 34 patients with hs-cTnTP 14 ng/
L on admission. After 6–8 h, patients of group I-B were reassessed by routine cardiac markers and
hs-TnT, in addition to one case of group I-A who was highly suspicious to be MI. Later, patients
were reclassiﬁed after conﬁrmatory cardiological diagnosis into group C, including cases of UA
(n= 17) and group D, representing cases of NSTEMI (n= 33).
Results: Results of the current study revealed that median serum levels of hs-TnT showed highly
signiﬁcant difference between patients with ACS and healthy subjects, and also between patients
with NSTEMI and those with UA. Receiver operating characteristic (ROC) curve analysis was
applied to assess the diagnostic performance of hs-TnT in discriminating patients from control
group. The best cutoff was 4.8 ng/L. This cutoff had a diagnostic sensitivity, speciﬁcity, PPV,
NPV and efﬁciency of 96%, 100%, 100%, 83.3% and 96.7% respectively. Another receiver oper-
ating characteristic (ROC) curve analysis was applied to assess the diagnostic performance of hs-
TnT for discriminating NSTEMI patients from UA patients. The best diagnostic cutoff for hs-
TnT was 13.7 ng/L. This had a diagnostic sensitivity, speciﬁcity, NPV, PPV and efﬁciency of
97%, 88.2%, 93.8%, 94.1% and 94% respectively.
Conclusion: Our study demonstrated highly signiﬁcant absolute and relative kinetic changes in hs-
TnT levels in patients with AMI. The hs-TnT can be used for early rule in patients with MI as it
could detect 97% of cases with MI whose Troponin I was negative and could detect 100% of cases
of MI after 6–8 h compared to Troponin I which could detect only 21.2% of cases. This can be of
great importance in the future introduction and use of the new high sensitive assay as a non-invasive
reliable diagnostic tool to replace the currently used invasive diagnostic techniques for patients with
ACS.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD), its acute form, and acute cor-
onary syndrome (ACS) are the leading cause of death all over
the world.1
ACS is the umbrella term of clinical signs and symptoms of
myocardial ischemia: unstable angina (UA), non-ST segment
elevation myocardial infarction (NSTEMI) and ST-segment
elevation myocardial infarction (STEMI).2
For initial assessment of a patient with ACS, clinical his-
tory is most useful, but risk factors, ECG, imaging techniques
and serum biomarkers all contribute in conﬁrming the diagno-
sis. Cardiac Troponin (cTn) I and T are the current gold stan-
dard for the detection of myocardial necrosis.3
Cardiac Troponin (cTn) has been identiﬁed as an indepen-
dent prognostic marker which can predict the near-, mid- and
even long-term outcome of patients with acute coronary
syndrome (ACS).4 In addition, several researches have shown
that Cardiac Troponin T is also useful to identify patients that
beneﬁt from anti-thrombotic therapy.5
The current universal deﬁnition of AMI requires a change
in cTn in patients with evidence of myocardial ischemia, with
at least one cTn value above the 99th percentile.4
However, there is also emerging evidence suggesting that
with the use of sensitive or high-sensitive cTn assays, a blood
sample collected 2 or 3 h after presentation might be appropri-
ate for an earlier rule in and rule out diagnosis of AMI com-
pared with the recommended second blood draw 6–9 h after
admission using conventional Troponin assay.3
Recently, improved cTn assay technology has led to the
development of fully automated cTn assays with higher sen-
sitivity and improved precision. These improvements allow
the measurement of cTn levels even in healthy individuals,and the novel assays have been shown to improve early
diagnostic accuracy for AMI in patients with acute chest
pain.6
2. Aim of the work
The aim of this study was to examine the ability of High-Sen-
sitivity Cardiac Troponin T for early detection of AMI in com-
parison with conventional Troponin assay. In addition, to
study the clinical utility of kinetic changes of High-Sensitivity
Cardiac Troponin T for diagnosis of ACS.
3. Subjects and methods
3.1. Subjects
This study was conducted on sixty subjects. Fifty patients
who presented to the emergency department in Ain Shams
University Hospital complaining of chest pain were highly
suspicious to have acute coronary syndrome, having either
no or non-speciﬁc ECG changes and their Cardiac Troponin
I level on admission was below the test threshold value
(100 ng/L). In addition to ten subjects serving as a healthy
control group, subjects were classiﬁed into the following
groups:
3.1.1. Patients’ group I
This group included ﬁfty patients who presented with chest
pain, no or non-speciﬁc ECG changes and their Troponin I
was less than test threshold value (100 ng/L). The hs-TnT
was assayed for all patients in this group and accordingly, they
were subdivided into two subgroups:
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(99th percentile) on admission, for this group no second
sample was needed except one who has a second sample
due to high probability of having an MI.
 Subgroup I-B included 34 patients, with hs-cTnTP 14 ng/L
on admission. For this group, a second sample was assayed
after 6–8 h.
Based on the ﬁnal diagnosis of the patients’ group (I), they
were reclassiﬁed into two subgroups, unstable angina (UA)
and Non-ST elevation MI (NSTEMI) and were given name
C and D respectively.
 Subgroup C: included 17 patients.
 Subgroup D: included 33 patients.
3.1.2. Control group 2
This group included ten (10) age- and sex-matched healthy
subjects serving as a healthy control group.
Exclusion criteria:
1. Patients diagnosed as ST segment elevation myocardial
infarction (STEMI).
2. Patients admitted following percutaneous coronary inter-
vention (PCI).
3. Patients who will have Cardiac Troponin I level on admis-
sion above test threshold (>100 ng/ml).
4. Patients with other diseases know to elevate serum tropo-
nins. (Chronic kidney disease, pulmonary embolism, sepsis,
stroke, cardiac surgery).
After an informed verbal consent, all individuals in this
study were subjected to the following:
 Detailed history taking and thorough clinical
examination.
 ECG (for patients only).
 Laboratory investigations:
– Lipid proﬁle (total cholesterol, TG,HDL-C andLDL-C).
– Routine kidney function tests.
– Complete blood count (CBC).
– Routine cardiac markers including CK-T, CK-MB and
Troponin I.
– High sensitive Troponin T (hs-TnT).
3.2. Sampling
3.2.1. First sample
Five milliliters (5 mL) of venous blood were withdrawn under
complete aseptic condition from patients on admission to ED
and from control. Two milliliters of which were collected on
EDTA for CBC. The remaining was left to clot into a plain vac-
utainer. Serum was separated by centrifugation at 1500g for
15 min and divided into two parts. The ﬁrst part was used for
immediate assay of routine blood chemistry including CK-T,
CK-MB, Troponin I and serum Creatinine and Lipid proﬁle
while the remaining part was stored within 2 h in aliquots at
620 C for subsequent assay of hs-TnT. Hemolysed samples
were discarded. Repeated freezing and thawing was avoided.A second sample was withdrawn after 6–8 h from all
patients group, left to clot into a plain vacutainer. Serum
was separated by centrifugation at 1500g for 15 min and
divided into two parts. The ﬁrst part was used for immediate
assay of CK-T, CK-MB and Troponin I while the remaining
part was stored within 2 h in aliquots at 620 C for subse-
quent assay of hs-TnT sample for those whose ﬁrst sample
was above 14 ng/L.
3.2.2. Troponin I
Troponin I was assayed on the AxSYM Troponin-I ADV by
Microparticle Enzyme Immunoassay (MEIA) (Lisnamuck,
Longford Co., Longford, Ireland) for the quantitative determi-
nation of Cardiac Troponin I in human serum or plasma on
the AxSYM System.
According to the manufacturer, the sensitivity of the assay
is 0.02 ng/mL. The method is linear up to 22.78 ng/mL.
3.2.3. High sensitive Troponin T (hs-TnT
The hs-TnT concentrations were measured using a commer-
cially available electrochemiluminescence immunoassay
‘‘ECLIA’’ supplied by roche company on cobas e 411.
3.2.3.1. Principle of the assay. Sandwich ECLIA principle in
which Troponin T is sandwiched by biotinylated monoclonal
anti-Troponin T antibody and monoclonal anti-Troponin T
antibody labeled with ruthenium complex. Then the sandwich
complex is bound to the solid phase via interaction of biotin
and streptavidin present on streptavidin coated microparticles
that are magnetically captured to the electrode surface. After
removal of the unbound substances, voltage is applied leading
to chemiluminescent emission to be measured by
photomultiplier.
3.2.3.2. Reagents supplied.
 Streptavidin-coated microparticles (transparent cap):
1 bottle containing 12 mL Streptavidin-coated microparti-
cle 0.72 mg/mL with preservative.
 Anti-Troponin T-Abbiotin (gray cap):
1 bottle containing 14 mL Biotinylated monoclonal anti-
Cardiac Troponin T antibody (mouse) in concentration
2.5 mg/L with phosphate buffer 100 mmol/L, pH 6.0, preser-
vative and inhibitors.
 Anti-Troponin T-AbRu(bpy)2 + 3 (black cap):
1 bottle containing 14 mLMonoclonal anti-Cardiac Tropo-
nin T-antibody (mouse) labeled with ruthenium complex
2.5 mg/L, phosphate buffer 100 mmol/L, pH 6.0 and
preservative.
3.2.3.3. Assay procedure. The specimens and cooled reagents
were brought to approximately 20 C and placed on the
reagent disk (20 C) of the analyzer with avoiding the forma-
tion of foam. The system automatically regulates the tempera-
ture of the reagents and the opening/closing of the bottles with
total duration of assay about 18 min.
1st incubation: 50 lL of sample, a biotinylated monoclonal
Cardiac Troponin T-speciﬁc antibody, and a monoclonal Car-
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complex react to form a sandwich complex.
2nd incubation: after addition of streptavidin-coated
microparticles, the complex becomes bound to the solid phase
via interaction of biotin and streptavidin.
The reaction mixture is aspirated into the measuring cell
where the microparticles are magnetically captured onto the
surface of the electrode. Unbound substances are then
removed with ProCell. Application of a voltage to the elec-
trode then induces chemiluminescent emission which is mea-
sured by photomultiplier.
Results are determined via a calibration curve which is
instrument-speciﬁc.
3.2.3.4. Calculation of results. The analyzer automatically cal-
culates the analyte concentration of each sample (either in
pg/mL, ng/mL or in optional in lg/L).
Before enrollment, an informed written consent was
obtained from each patient after full explanation of the study
protocol, and the protocol was reviewed and approved by our
local Institutional Human Research Committee as it conforms
to the ethical guidelines of the 1975 Declaration of Helsinki, as
revised in 2002.
3.3. Statistical methods
IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012) was used
for data analysis. Date were expressed as Mean± SD for quan-Table 1 Descriptive statistics of group (Patients’ group) and grou
Parameters Group (n= 50) median (IQR)a
Age (years) 50 (50–67)
Cholesterol (mg/dL) 175 (138–199)
TG (mg/dL) 116 (79–191)
HDL (mg/dL) 35 (30–46)
LDL (mg/dL) 106 (79–133)
S.Cr (mg/dL) 1.1 (0.9–1.4)
CK-T1 (l U/L) 97 (66–163)
CK-MB1 (l U/L) 18 (10–28)
Troponin I 1 (ng/L) 10 (5–42.5)
hs-TnT1(ng/L) 41.5 (12.9–141.3)
a IQR= Interquartile range.
Table 2 Descriptive statistics of patients’ subgroup (I-A and I-B).
Parameters Subgroup (-A) n= 16
Median (IQR)a
Age (years) 60 (54–66)
Cholesterol (mg/dL) 144 (127–195)
TG (mg/dL) 100 (53–132)
HDL (mg/dL) 39 (27–50)
LDL (mg/dL) 93 (68–135)
S.Cr (mg/dL) 1 (0.8–1.1)
CK-T1 (l U/L) 133 (54–169)
CK-MB1 (l U/L) 12 (7–23)
Troponin I 1 (ng/L) 10 (0–10)
hs-TnT1 (ng/L) 10.6 (6.7–12.9)
p> 0.05 = Nonsigniﬁcant.
a IQR= Interquartile range.
* p< 0.05 = Signiﬁcant.
** p< 0.01 = Highly signiﬁcant.titative parametric measures in addition to Median Percentiles
for quantitative non-parametric measures and both number
and percentage for categorized data (see Tables 1 and 2).
4. Results
Receiver operating characteristic (ROC) curve analysis was
applied to assess the diagnostic performance of hs-TnT in dis-
criminating patients’ group () from control group (II) as sum-
marized in Table 3. The best cutoff for discriminating group
(II) from group () is 4.8 ng/L. This cutoff has a diagnostic sen-
sitivity of 96%, speciﬁcity of 100%, positive predictive value
(PPV) of 100%, negative predictive value (NPV) of 83.3%,
efﬁciency of 96.7% and AUC of 0.966 as shown in Fig. 1
(see Tables 4 and 5).
A second receiver operating characteristic (ROC) curve
analysis was applied to assess the diagnostic performance of
hs-TnT in discriminating group D (NSTEMI) from group C
(UA) as summarized in Table 6. The best cutoff for discrimi-
nating group (D) from group (C) is 13.7 ng/L. This cutoff
had a diagnostic sensitivity of 97%, speciﬁcity of 88.2%, posi-
tive predictive value (PPV) of 94.1%, negative predictive value
(NPV) of 93.8%, efﬁciency of 94% and AUC of 0.954 as
shown in Fig. 2.
According to the result of ﬁrst assayed sample, patients
with hs-TnT > 14 ng/L (group I-B) were reassessed after 6–
8 h for their cardiac markers including CK-T, CK-MB, Tropo-
nin I and hs-TnT. Only one case which had on admission hs-p II (Control group). Data are expressed as median and IQRa.
Group II (n= 10) median (IQR)a P
51 (47–53) <0.05*
156 (108–224) >0.05
81 (52–263) >0.05
26.5 (21–45) >0.05
109 (59–143) >0.05
0.8 (0.7–0.9) <0.01**
142 (135–160) >0.05
14 (12–18) >0.05
0.01 (0.01–0.02) <0.01**
3.45 (3.075–4.025) <0.01**
Data are expressed as median and IQRa.
Subgroup (-B) n= 34 P
Median (IQR)a >0.05
59 (49–68) >0.05
177 (146–202) <0.05*
151 (84.5–197) >0.05
35 (30–46) >0.05
114 (85–133) >0.05
1.1 (0.9–1.5) >0.05
144 (92–306) <0.05*
22 (12–29) <0.05*
25 (10–50) <0.01**
92 (40–257.3) <0.01**
Table 3 Diagnostic performance of hs-TnT (ng/L) in group versus group II at cut-off Level 4.8.
Parameter Cutoﬀ Sensitivity (%) Speciﬁcity (%) NPV (%) PPV (%) Eﬃciency (%)
hs-TnT (ng/L) 4.8 96 100 83.3 100 96.7
• Best cutoﬀ 4.8 ng/mL
AUC
hs-TnT (ng/L) 0.966
Figure 1 Receiver operating characteristic (ROC) curve analysis
showing the diagnostic performance of hs-TnT (ng/L) in patients
versus healthy controls.
The diagnostic utility of High-Sensitivity Cardiac Troponin T 5TnT sample less than 14 ng/L (group I-A) was reassayed for
the same test after 6–8 h, as it was highly suspicious to be a
case of NSTEMI according to the cardiologists and their diag-
nosis was subsequently conﬁrmed by angiography. For each
patient in the total re-evaluated cases (n= 35: thirty-four of
them included as group I-B and 1 sample from group 1-A),
absolute and relative change in the studied markers was calcu-
lated. These data are described in Table 7.
N.B: Absolute change is calculated by simple substraction
of both results substraction (2nd sample concentration – 1st
sample concentration), while percent change is calculated as
Conc: of 2nd sample Conc: of 1st sample
Conc: of 1st sample
 100
ðMueller et al:; 2012Þ
Table 7 revealed that the Absolute change of CK-T, CK-
MB, Troponin I and hs-TnT is 46, 21, 10 and 152 respectively,
while the relative (percent) change is 59, 81, 50 and 145 respec-
tively. Therefore, hs-TnT has the highest absolute and percent
change value between the ﬁrst and second samples (see Fig. 3).Table 4 Statistical comparison between Sample 2 and Sample 1 as re
Parameters Sample 1
Median (IQR)a
CK-T (l U/L) 93 (68–136)
CK-MB (l U/L) 22 (12–30)
Troponin I (ng/L) 30 (10–50)
hs-TnT (ng/L) 83 (37–255)
a IQR= Interquartile range.
** <0.01 = Highly signiﬁcant.5. Discussion
Myocardial infarction is a major cause of death and disability
worldwide.7
The term acute coronary syndrome refers to unstable
angina, non-ST-segment elevation and ST-segment elevation
myocardial infarction. One-fourth of acute coronary syndrome
patients are diagnosed with ST-segment elevation myocardial
infarction, and the remainders have unstable angina or non-
ST-segment MI (NSTEMI).8
The term ‘‘acute coronary syndrome’’ is useful because the
initial presentation and early management of unstable angina,
STEMI, and NSTEMI frequently are similar.9
Rapid identiﬁcation of acute myocardial infarction is criti-
cal for the initiation of effective evidence-based medical treat-
ment and management.7
Over the past two decades, Cardiac Troponin has been
adopted as the preferred biomarker for the diagnosis of acute
MI, a position reafﬁrmed in recent consensus guidelines.10
Because of improved analytical performance of the new
high sensitive Cardiac Troponin T assay (hs-cTnT), cTnT con-
centrations within reference intervals can now be measured in
most healthy individuals, and imprecision at the 99th percen-
tile reference value concentrations is below 10% CV. With a
decrease in the diagnostic cutoff by implementation of more
sensitive and precise assays, sensitivity is further increased
but speciﬁcity is decreased owing to detection of more acute,
subacute, and chronic cardiac diseases not related to ACS,
such as heart failure and cardiomyopathies.11
An abnormal Troponin-T is now reported as >14 ng/L
which is equivalent to (0.014 lg/mL) by older 4th generation.
So, unless a laboratory is using the new 5th generation cTn
assay (hs-cTn), compliance with the current guidelines is
impossible.12
In view of the previous observations, the aim of the present
study was to examine the ability of High-Sensitivity Cardiac
Troponin T (hs-TnT) for early detection of AMI in compari-
son with conventional Troponin assay. In addition, to study
the clinical utility of kinetic changes of hs-TnT for diagnosis
of ACS.
This study was conducted on ﬁfty patients from both sexes;
36 male (72%) and 14 (28%) female presenting to the Emer-
gency Department at Ain Shams University Hospital withgards cardiac markers using Wilcoxon signed-rank test (n= 35).
Sample 2 Z P
Median (IQR)a
144 (93–313) 3.9 <0.01**
39 (24–65) 5.1 <0.01**
60 (10–130) 4.2 <0.01**
284 (97–992) 5.2 <0.01**
Table 5 Descriptive statistics of patients’ subgroups UA and NSTEMI (C and D), data are expressed as median and IQRa.
Parameters Subgroup (C) n= 17 Subgroup (D) n= 33 p
Median (IQR)a Median (IQR)a >0.05
Age (years) 55 (50–64) 60 (51–70) >0.05
Cholesterol (mg/dL) 169 (128–200) 175 (44–200) >0.05
TG (mg/dL) 109 (54–163) 145 (84–197) >0.05
HDL (mg/dL) 39 (28.5–48) 35 (29.5–46) >0.05
LDL (mg/dL) 101 (72–132) 112 (82–134) >0.05
S.Cr (mg/dL) 1 (0.8–1.1) 1.1 (0.9–1.56) >0.05
CK-T1 (l U/L) 132 (57–175) 93 (68–149) >0.05*
CK-2 (l U/L) 104 (48–174) 145 (94–346) <0.05*
CK-MB1 (l U/L) 11 (6–22) 22 (13–31) <0.05**
CK-MB (l U/L) 12 (7–22) 42 (35–75) <0.01*
Troponin I 1 (ng/L) 10 (0–10) 30 (10–50) <0.05**
Troponin I 2 (ng/L) 10 (0–10) 60 (10–160) <0.01**
hs-TnT1 (ng/L) 12.5 (8.6–13.2) 83 (39–260) <0.01
a IQR= Interquartile range.
Table 6 Diagnostic performance of hs-TnT (ng/mL) in group D (NSTEMI) versus group C (UA) at cut-off level 13.7.
Parameter Cutoﬀ Sensitivity (%) Speciﬁcity (%) NPV (%) PPV (%) Eﬃciency (%)
hs-TnT (ng/L) 13.7 97 88.2 93.8 94.1 94
• Best cutoﬀ 13.7 ng/mL
AUC
Hs-TnT (ng/L) 0.954
Figure 2 Receiver operating characteristic curve (ROC) analysis
showing the diagnostic performance of Hs-TnT (ng/L) in patients’
subgroup D (NSTEMI) versus C (UA).
Table 7 Descriptive statistics of absolute and relative change
of different cardiac markers between ﬁrst and second samples
(n= 35).
Parameter Median IQRa
CK-T1 93 (68–136)
CK-T2 144 (93–313)
Absolute change 46 (8–109)
Relative change (%) 59 (8–127)
CK-MB1 22 (12–30)
CK-MB2 39 (24–65)
Absolute change 21 (10–37)
Relative change (%) 81 (39–178)
Troponin I 1 30 (10–50)
Troponin I 2 60 (10–130)
Absolute change 10 (0–80)
Relative change (%) 50 (0–507)
hs-TnT 1 83 (37–255)
hs-TnT 2 284 (97–992)
Absolute change 152 (30–660)
Relative change (%) 145 (35–408)
6 M. Mohsen, A. Shawkychest pain. On history taking, thirty-nine (78%) of them gave
history of hypertension, 33 (66%) of smoking, 39 (78%) were
diabetics, 16 (32%) had obesity, 24 (48%) gave history of dysl-
ipidemia, 21 (42%) gave family history of coronary artery dis-
eases and 36 (72%) of them gave history of having previous
ischemic attacks.
All patients included had normal or non-speciﬁc ECG
changes. On admission, blood samples were withdrawn to
measure routine cardiac enzymes and Troponin I, upon which
patients were selected in the study. All Troponin I positivepatients were excluded, and only Troponin I negative subjects
were included (i.e. on admission Troponin I sample was less
than 0.1 ng/ml; less than 100 ng/L).
The hs-TnT was measured for the entire Troponin I nega-
tive patients. Accordingly, they were further classiﬁed into
two subgroups using a cutoff 14 ng/L, which represents the
99th percentile value of hs-TnT.12
According to the result of ﬁrst sample, patients with hs-
TnT > 14 ng/L (group I-B) were reassessed after 6–8 h by rou-
tine cardiac markers (CK-T,CK-MB), Troponin I and hs-TnT.
Only one case which had on admission hs-TnT sample less
78.8 78.8
69.7 63.6
21.2
3 0
12.1 9.1
21.2 21.2
30.3 36.4
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97 100
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Figure 3 A bar chart showing comparison between different studied parameters as regards the ability of the high sensitive assay to
discriminate true positive results of MI among the positively clinically diagnosed patients. It shows that hs-TnT assay detected 97% of MI
cases at the time that troponin I could not detect any case on admission. After 6–8 h troponin I detected 21.2% versus 100% for hs-TnT.
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6–8 h, as it was highly suspicious to be a case of NSTEMI
according to the cardiologists and their diagnosis was subse-
quently conﬁrmed by angiography. In addition, ten age- and
sex-matched apparently healthy subjects served as a healthy
control group.
After conﬁrmatory cardiological assessment, patients
(n= 50) were re-classiﬁed into 2 subgroups, subgroups C
(UA) and D (NSTEMI).
Subgroup C consists of 17 cases who had UA, 15 of them
are those of group I-A (on admission hs-TnT < 14 ng/L) plus
2 cases from group I-B.
Regarding subgroup D, it consists of 33 cases where con-
ﬁrmed to be NSTEMI. 32 of them (97%) are of group I-B
plus 1 case from group I-A. (This means that the ﬁrst sample
of hs-TnT could detect 97% of NSTEMI cases on
admission.)
In the present study, the median of hs-TnT in the patient
group was 41.5 ng/L versus 3.45 ng/L in the control group.
This was similar to Laufer et al.13 who estimated that the med-
ian hs-TnT in their control group was 3.7 ng/L.
Results of the present study revealed that there was a highly
signiﬁcant difference between patients and controls in their hs-
TnT on admission (p< 0.01). These results are in agreement
with those of Laufer et al.13 and Herna´ndez-Romero et al.14,
who had similar results. They suggested that serum levels of
hs-TnT are increased with the pathogenic progress of CAD
leading to presence of quantiﬁable circulating levels of hs-TnT.
There was also a highly signiﬁcant difference (p< 0.01)
noticed between both groups (patients and control) as regards
serum creatinine as all controls were below 1 mg/dl while most
of patients had serum creatinine above 1 mg/dl, which tend to
rise with progression of CAD. The same ﬁnding was obtained
by Laufer et al.13 who found that median serum creatinine is
higher in patients with CAD than healthy subjects, and the dif-
ference was obvious in each patient subgroup indicating more
rise with progression of the disease.
Interestingly, there was no signiﬁcant statistical difference
between the patient and control group regarding lipid proﬁle
results although most of patients gave history of dyslipidemia.
This ﬁnding is explained by that most of included patients were
on lipid lowering drugs. This difference was in agreement withLaufer et al.13 who had non-signiﬁcant difference in lipid pro-
ﬁle between patient and control of their study, in contrast to
Herna´ndez-Romero et al.14 who had signiﬁcant difference in
total cholesterol between patient and control. This controversy
could be due to their larger sample size (n= 615,198 respec-
tively) compared to the present study (n= 50).
The present study revealed that the median hs-TnT in
group C was 12.5 ng/L and 83 ng/L in group D. These values
were close to those of Mueller et al.6 who found that median
hsTnT in UA and NSTEMI was 14 and 92 ng/L respectively.
In addition, on admission serum hs-TnT level had a highly
signiﬁcant difference (p< 0.01) in patients with NSTEMI
than those who had UA. This was consistent with Reichlin
et al.7 and Giannitsis et al.15 who assured that cardiac high
sensitive troponin levels at presentation in patients whose ﬁnal
diagnosis was unstable angina were signiﬁcantly lower than
those in patients whose ﬁnal diagnosis was acute myocardial
infarction.
By comparing groups C and D regarding cholesterol, TG,
HDL, LDL, S.creatinine, there was no signiﬁcant difference
(p> 0.05). These ﬁndings are consistent with other researchers
such as Reichlin et al.7. It can be attributed to being common
risk factors for all patients of CAD.
The present study demonstrated a non-signiﬁcant associa-
tion between hs-TnT levels and the common risk factors for
ACS among patients (C and D). This can be explained by that
most of patients in both subgroups are similar as regards
smoking, hypertension, diabetes, obesity, hyperlipidemia, fam-
ily history, and ischemic history and they are only different in
serum hs-TnT.
A cornerstone in the present study was the assessment of
the correlation between hs-TnT and the other cardiac markers
(total CK, CK-MB and Troponin I). A remarkable ﬁnding was
that there was no correlation between hs-TnT level and total
CK and CK-MB levels (p> 0.05) in patients with NSTEMI
and UA. Similarly, Jeremias and Daubert16 had the same
results. They explained it by that CK and its isoform CK-
MB are not speciﬁc for the heart, they are present in many
extracardiac tissues, being released in many injuries other than
cardiac (e.g., muscle injury)16, but troponin (I or T) has dem-
onstrated nearly absolute myocardial tissue speciﬁcity as well
as high clinical sensitivity for myocardial ischemia.
8 M. Mohsen, A. ShawkyIn the 35 patients, who were reassayed for hs-TnT after 6–
8 h, both absolute and relative (%) change values are calcu-
lated. Absolute change was attained by substraction (2nd sam-
ple concentration – 1st sample concentration). Relative change
(percent change) was obtained by the equation7:
conc: of 2nd sample conc: of 1st sample
conc: of 1st sample
 100
By comparing absolute and relative change in concentrations
of different studied markers, hs-TnT had the highest median
absolute change (152 ng/L) compared to CK-T, CK-MB and
Troponin I (median = 46 u/L, 21 u/L, 10 ng/L respectively).
Similarly, comparison between percent change in the same
markers revealed that Hs-TnT had the largest relative change
(median: 145%, IQR: 35-408) compared to CK-T, CK-MB
and Troponin I (59%, 21% and 50% respectively). This was
in agreement with several investigators9,11,17 who have pro-
posed relative delta changes between 30% and 250% to
increase the diagnostic speciﬁcity and thus improve diagnosis
of AMI.
Also, this was in agreement with Agewell et al.18 who men-
tioned that in a study of change of hs-TnT within 6 h compar-
ing patients with a ﬁnal diagnosis of NSTEMI who initially
presented with a negative troponin and patients with a ﬁnal
diagnosis of UA, it was found that a change >117% from
the baseline increased speciﬁcity for MI.
This is not in contrast to the result of the comparative study
between the studied cardiac markers which showed highly sig-
niﬁcant change between the second and ﬁrst samples in all 4
cardiac markers used. However, hs-TnT has the highest z value
(=5.2).
Moreover, this study investigated the diagnostic utility of
hs-TnT in discriminating the patient from the healthy control
group. The best cutoff was 4.8 ng/L. This cutoff had a diagnos-
tic sensitivity and speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and efﬁciency of 96%,
100%, 100%, 83.3%, and 96.7% respectively.
Also receiver operating characteristic (ROC) curve analysis
was applied to assess the diagnostic performance of hs-TnT for
discriminating NSTEMI patients from UA patients. The best
diagnostic cutoff for hs-TnT was 13.7 ng/mL. This had a diag-
nostic sensitivity of 97%, speciﬁcity 88.2%, negative predictive
value 93.8%, positive predictive value 94.1% and efﬁciency
94%. The area under curve (AUC) was 0.966. However, Fre-
und et al.19 recommended 14 ng/L to rule in MI. At such cut-
off, sensitivity was 89% and speciﬁcity was 82%.
Similarly, Reichlin and co-workers7 used the same cutoff
14 ng/L to rule in MI with a sensitivity of 95% and speciﬁcity
of 80%.
Finally, by using high sensitive Troponin T assay the num-
ber of patients with ﬁnal diagnosis of unstable angina was
decreased from 50 to 17 with a corresponding increase of the
number of NSTEMI patients, which is due to the inaccuracy
of the initial Troponin I as compared to the hs-TnT.
The diagnostic performance of the new more sensitive and
precise hs-TnT assay was evaluated at the 13.7 ng/L cutoff
compared with the diagnostic performance of the conventional
cTnI assay at the 99th percentile cutoff (0.3 lg/L) for the pre-
diction of evolving NSTEMI. For this purpose the sensitivities
and speciﬁcities of the baseline and early follow-up samples
were calculated and compared with the standard cTnI at therecommended cutoff of 0.3 lg/L which corresponds to the con-
centration at which the assay imprecision is below 10% CV as
recommended by Tate and Panteghini.20 In addition, the use-
fulness of the delta change of the follow-up sample within 6–
8 h from baseline was tested.
It was found that the 13.7 ng/L cutoff used with the hs-TnT
assay allowed an earlier diagnosis of evolving NSTEMI com-
pared with the standard cTnI at the 0.3 lg/L cutoff concentra-
tion. 99th percentile hs-cTnT concentrations were already
present on admission in 97% of NSTEMI patients, and
increased gradually to 100% within 6 h. Compared with the
conventional cTnI assay at the 99th percentile, the hs-TnT
assay on initial measurement identiﬁed more patients with
myocardial necrosis (97% versus 0%, p< 0.0001). This can
be explained by the increased sensitivity of the new hs-TnT.
6. Conclusion
We found signiﬁcantly higher level of serum hs-TnT in ACS
patients compared to controls. In addition serum hs-TnT level
within ACS patients was able to discriminate cases of AMI
from cases with UA. Moreover, hs-TnT is much more better
for early rule in of patients with MI as it could detect 97%
of cases with MI whose Troponin I was negative and could
detect 100% of cases of MI after 6–8 h compared to Troponin
I could detect only 21.2% of cases. Also, this study found high
signiﬁcant absolute and relative kinetic changes in hs-TnT in
patients with AMI. Hence, this study highlights the utility of
hs-TnT as a reliable assay for Cardiac Troponins for early
diagnosis of AMI.
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